Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression

Galunisertib (Gal) is a transforming growth factor (TGF-β) blockade which is being investigated as a potential tumor immunotherapy candidate drug in clinical trials. However, primary or acquired resistance is often found in the recruited cancer patients, which limits its clinical application. Tumor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Theranostics
Hlavní autoři: Shi, Linlin, Sheng, Jianyong, Wang, Mengli, Luo, Han, Zhu, Jun, Zhang, Bixiang, Liu, Zhi, Yang, Xiangliang
Médium: Artigo
Jazyk:Inglês
Vydáno: Ivyspring International Publisher 2019
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6592171/
https://ncbi.nlm.nih.gov/pubmed/31281535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.35131
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky